Accelerating promising immunotherapy treatments
Immunotherapy is a collection of approaches that train and direct the body’s natural immune system to attack cancer cells. As one of the pillars of our strategic plan, we are focused on immunotherapy to accelerate promising treatments for multiple myeloma patients.
We are driving groundbreaking and collaborative immunotherapy research programs that focus on several specific types of immunotherapy that show promise for myeloma, including chimeric antigen receptor T-cell (CAR-T) therapy, vaccines and monoclonal antibodies. This data integrates with genomic and patient immune information so we can find answers to critical questions about myeloma patient immunity and accelerate novel immunotherapy approaches.
Areas of focus
The Immune Atlas is an exciting precision medicine initiative designed to comprehensively gather data surrounding patient immunity and establish a gold-standard immune profiling platform for clinical studies and research. It details the immune landscape in myeloma and how it changes throughout the course of the disease and treatment.
- Beth Israel Deaconess Medical Center
- Emory University
- Mt. Sinai School of Medicine
- Mayo Clinic
- Washington University (St. Louis)
We are improving efficiencies and expanding clinical trials in immune-oncology studies to better understand individual patients’ immune responses. Through collaborative studies at the Multiple Myeloma Research Consortium (MMRC), we are conducting platform trials and investigating molecular targets and novel agents to get new therapies to patients more quickly.
- Multiple Myeloma Research Consortium (21 sites)
We are generating data and supporting research to better understand smoldering multiple myeloma patients with the aim of improving patient outcomes and ultimately preventing disease progression.
- Dana-Farber Cancer Institute
Every immune system is different
Dr. Paul Richardson, clinical program leader and director of clinical research for the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, discusses why immune therapies can dramatically improve patient outcomes, the types of trials that are critical to research and how the MMRF is fostering collaboration around immunotherapy research.